Kikuchi K, McCormick C I, Neuwelt E A
J Neurosurg. 1984 Dec;61(6):1085-90. doi: 10.3171/jns.1984.61.6.1085.
This investigation was conducted to examine the immunosuppressive potential of phenytoin in vivo and to document a correlation between phenytoin therapy and depressed lymphocyte responsiveness to mitogens. It was thought that phenytoin, the most widely used anticonvulsant agent, may play some role in the immunosuppression seen in brain-tumor patients. The effect of phenytoin on mitogen-stimulated lymphocyte function was evaluated by tritiated (3H)-thymidine incorporation and lymphocyte nuclear size distribution. Lymphocytes from either phenytoin-treated or normal rabbits were incubated for 90 hours in culture medium in the presence of three mitogens: phytohemagglutinin (PHA), concanavalin A (Con A), and pokeweed mitogen (PWM). Significant suppression of mitogen-induced activation of the lymphocytes from treated animals was demonstrated. The present studies suggest a possible connection between phenytoin therapy and altered immune competence in brain-tumor patients.
本研究旨在检测苯妥英在体内的免疫抑制潜力，并记录苯妥英治疗与淋巴细胞对丝裂原反应性降低之间的相关性。人们认为，苯妥英作为使用最广泛的抗惊厥药物，可能在脑肿瘤患者出现的免疫抑制中发挥某种作用。通过氚化（3H）胸腺嘧啶核苷掺入法和淋巴细胞核大小分布评估苯妥英对丝裂原刺激的淋巴细胞功能的影响。将来自苯妥英治疗组或正常兔子的淋巴细胞在含有三种丝裂原的培养基中培养90小时，这三种丝裂原分别是植物血凝素（PHA）、刀豆蛋白A（Con A）和商陆丝裂原（PWM）。结果表明，苯妥英显著抑制了处理组动物淋巴细胞的丝裂原诱导激活。目前的研究表明，苯妥英治疗与脑肿瘤患者免疫能力改变之间可能存在联系。
